PINAL PATEL: Open Payments
NPI 1427190891 · GLASSBORO, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$477 in 26 payments from 12 companies in 2025. Trend: 2023 $392 · 2024 $455 · 2025 $477
Food & beverage: $477
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $98 |
| Astellas Pharma US Inc | 4 | $79 |
| Novo Nordisk Inc | 4 | $73 |
| Corcept Therapeutics | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| PFIZER INC. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Exact Sciences Corporation | 1 | $22 |
| Abbott Laboratories | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
Products named: Veozah, VRAYLAR, Korlym, Ozempic, AIRSUPRA, UBRELVY, INJECTAFER, Cologuard Collection Kit.
Industry payments across NJ — which companies pay providers there.
